Literature DB >> 25433440

Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol.

Ursula Pluschnig1, Werner Haslik, Günther Bayer, Afschin Soleiman, Rupert Bartsch, Wolfgang Lamm, Günther G Steger, Christoph C Zielinski, Robert M Mader.   

Abstract

PURPOSE: In a longitudinal observation, extravasation of antitumoural compounds and the efficacy of its structured interdisciplinary management were assessed in a routine setting.
METHODS: One hundred sixty-nine patients with extravasation of cytotoxics were managed according to a prospective approach documenting the extravasated compound, localisation, duration until full symptom resolution and sequelae. Surgery was implemented in the case of failure of conservative measures.
RESULTS: In 155 (91.7 %) out of 169 patients, conservative management was successful (surgical intervention, 14 patients). Extravasations of anthracyclines (N = 44), platinum compounds (N = 41), vinca alkaloids (N = 20) and taxanes (N = 19) were often associated with erythema, oedema and pain. The median period until full resolution of symptoms differed among the administered cytotoxics (anthracyclines, 55 days; taxanes and vinca alkaloids, 27 days; platinum compounds, 14 days) with statistical significance between the vesicants. Histologically, surgically resected specimens showed extensive necrotic areas with inflammatory infiltrates at the periphery of the removed lesions.
CONCLUSIONS: In a routine setting, the standardised management of cytotoxic extravasations by an interdisciplinary task force resulted in a satisfactory outcome. When surgical intervention was indicated, complete remission of the lesions within a median of 14 days reduced the delay in the administration of further chemotherapy to a minimum. The proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25433440     DOI: 10.1007/s00520-014-2535-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  22 in total

Review 1.  Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

Authors:  Todd A Theman; Tristan L Hartzell; Indranil Sinha; Kathleen Polson; Jeffrey Morgan; George D Demetri; Dennis P Orgill; Suzanne George
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

2.  Local soft tissue toxicity following cisplatin extravasation.

Authors:  S Fields; J Koeller; R L Topper; G Guritz; D Von Hoff
Journal:  J Natl Cancer Inst       Date:  1990-10-17       Impact factor: 13.506

3.  Skin ulceration potential of paclitaxel in a mouse skin model in vivo.

Authors:  G Bertelli; M A Cafferata; A Ardizzoni; A Gozza; R Rosso; D Dini
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

4.  Experimental and clinical studies of ulcers induced with adriamycin.

Authors:  J A Petro; W P Graham; S H Miller; T Overholt; T Fallon
Journal:  Surg Forum       Date:  1979

5.  Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs.

Authors:  R J Ignoffo; M A Friedman
Journal:  Cancer Treat Rev       Date:  1980-03       Impact factor: 12.111

6.  Histologic changes induced in skin by extravasation of doxorubicin (adriamycin).

Authors:  J Bhawan; J Petry; M E Rybak
Journal:  J Cutan Pathol       Date:  1989-06       Impact factor: 1.587

7.  Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.

Authors:  H T Mouridsen; S W Langer; J Buter; H Eidtmann; G Rosti; M de Wit; P Knoblauch; A Rasmussen; K Dahlstrøm; P B Jensen; G Giaccone
Journal:  Ann Oncol       Date:  2006-12-21       Impact factor: 32.976

8.  Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results.

Authors:  G Bertelli; D Dini; G B Forno; A Gozza; S Silvestro; M Venturini; R Rosso; P Pronzato
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  Extravasation: a hazard of intravenous therapy.

Authors:  M E MacCara
Journal:  Drug Intell Clin Pharm       Date:  1983-10

10.  Indocyanine green video angiography predicts outcome of extravasation injuries.

Authors:  Werner Haslik; Ursula Pluschnig; Günther G Steger; Christoph C Zielinski; K F Schrögendorfer; Jakob Nedomansky; Rupert Bartsch; Robert M Mader
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

View more
  5 in total

Review 1.  [Management of chemotherapy side effects and their long-term sequelae].

Authors:  Isabella M Zraik; Yasmine Heß-Busch
Journal:  Urologe A       Date:  2021-06-29       Impact factor: 0.639

2.  Tissue distribution of epirubicin after severe extravasation in humans.

Authors:  Jakob Nedomansky; Werner Haslik; Ursula Pluschnig; Christoph Kornauth; Christine Deutschmann; Stefan Hacker; Günther G Steger; Rupert Bartsch; Robert M Mader
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-27       Impact factor: 3.333

Review 3.  Extravasation emergencies: state-of-the-art management and progress in clinical research.

Authors:  Ursula Pluschnig; Werner Haslik; Rupert Bartsch; Robert M Mader
Journal:  Memo       Date:  2016-12-05

4.  Ultrasonographic assessment of an induration caused by extravasation of a nonvesicant anticancer drug: A case report.

Authors:  Mari Abe-Doi; Ryoko Murayama; Koichi Yabunaka; Hidenori Tanabe; Chieko Komiyama; Hiromi Sanada
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

Review 5.  Plastic Surgery in the Multimodal Treatment Concept of Soft Tissue Sarcoma: Influence of Radiation, Chemotherapy, and Isolated Limb Perfusion on Plastic Surgery Techniques.

Authors:  Nicolai Kapalschinski; Ole Goertz; Kamran Harati; Maximilian Kueckelhaus; Jonas Kolbenschlag; Marcus Lehnhardt; Tobias Hirsch
Journal:  Front Oncol       Date:  2015-12-01       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.